Cleo Diagnostics (ASX:COV) Other Long-Term Liabilities : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Other Long-Term Liabilities?

Cleo Diagnostics's other long-term liabilities for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cleo Diagnostics Other Long-Term Liabilities Historical Data

The historical data trend for Cleo Diagnostics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Other Long-Term Liabilities Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Other Long-Term Liabilities

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Other Long-Term Liabilities	-	-	-

Cleo Diagnostics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Cleo Diagnostics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines